)
Diaceutics (DXRX) investor relations material
Diaceutics Q4 2025 TU earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Reported revenues expected at £38.5 million for FY 2025, a 20% increase year-over-year, with a return to profitability and strong commercial momentum.
Constant currency revenue growth projected at 24%, aligning with analyst consensus.
Record order book of at least £36.8 million and ARR exceeding £20.3 million, reflecting robust recurring revenue growth.
Expanded customer base, with 12% growth in therapeutic brands to 95 and three new enterprise-wide customers added.
Second PMx commercialisation partnership signed, supporting further commercial growth.
Financial highlights
Adjusted EBITDA expected to surpass analyst consensus, with approximately 75% year-over-year growth and a margin of about 19%.
Profit after tax achieved, marking a return to profitability.
Annual Recurring Revenue (ARR) up 21% to over £20.3 million, with USD ARR growth exceeding 30%.
Order book up 48% year-over-year to at least £36.8 million.
Ten enterprise-wide engagements live across 36 brands, generating £13.0 million in ARR.
Outlook and guidance
25% revenue growth expected for FY 2026.
Continued acceleration in precision medicine adoption among pharma and biotech customers.
Ongoing enhancements to the DXRX platform driving operational leverage and expanded revenue opportunities.
- TimeTickerHeadlineOpen
- XANO
Profitability and cash flow surged despite mixed segment trends; dividend proposed. - BERGEPAINT
Record gross margins and strong segment growth, but net profit declined. - ROK
Double-digit sales and EPS growth drive raised 2026 guidance and strong segment performance. - AAVAS
AUM up 15.4% YoY, PAT up 13%, GNPA at 1.19%, and NCD security cover at 110.42%. - BMY
Growth Portfolio drives double-digit growth and margin gains as legacy products decline. - PTON
Profitability rose sharply as Adjusted EBITDA grew 39% and net loss narrowed, despite lower revenue. - OESX
Revenue and profitability improved in Q3 2026, with raised guidance and major contract wins. - VOD
Q3 service revenue up 5.4%, EBITDAaL up 2.3%, and FY26 guidance at the upper end. - PNDORA
2025 organic growth was 6% with 23.9% EBIT margin; 2026 focuses on platinum-plated transition. - LQDT
Strong Q1 profit growth and market share gains set the stage for continued EBITDA expansion.
Next Diaceutics earnings date
Next Diaceutics earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage
)
)